search
Back to results

Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

Primary Purpose

Acute Kidney Injury

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Brilliance device sensor
Sponsored by
MediBeacon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Acute Kidney Injury focused on measuring Glomerular Filtration Rate

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male and female adults age 18 and older
  • 2 age cohorts to be recruited: 18 - 50 years of age and 51+ years or older
  • Skin color groups to be recruited in accordance with the Fitzpatrick Skin Scale (I - VI)
  • Participants willing to sign the Institutional Review Board (IRB) approved informed consent form prior to the initiation of any study specific procedures.

Exclusion Criteria:

  • History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape)
  • Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial
  • Significant scarring, tattoos or alterations in pigmentation on the standardized sensor locations that would alter sensor readings versus other areas of the skin

Sites / Locations

  • St. Louis Clinical Trials

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Participants with Brilliance sensor placement

Arm Description

Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours

Outcomes

Primary Outcome Measures

Mean Background Fluorescence
Two separate Brilliance device sensors will be attached via standard adhesive pads to the left and right pectoralis major on each participant. Fluorescence measurements will be collected directly by the MediBeacon Transdermal GFR Measurement System Brilliance device, and will be continuously collected throughout the 48 hour study.

Secondary Outcome Measures

Full Information

First Posted
January 17, 2019
Last Updated
January 7, 2020
Sponsor
MediBeacon
search

1. Study Identification

Unique Protocol Identification Number
NCT03810833
Brief Title
Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System
Official Title
A Study of Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
September 16, 2019 (Actual)
Primary Completion Date
September 23, 2019 (Actual)
Study Completion Date
September 23, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MediBeacon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.
Detailed Description
The MediBeacon Transdermal GFR Measurement System investigational is intended to measure the Glomerular Filtration Rate (GFR) in patients with normal or impaired renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent (MB-102) over time. The device utilized in this study is the Brilliance device. Approximately 1 male and 1 female from each age cohort (18-50 years; 51+ years) and clustered Fitzpatrick Skin Scale groups (I-II [Light, pale white; white, fair]; III-IV [Medium, white to olive; olive, moderate brown]; and V-VI [Brown, dark brown; black, very dark brown to black]) will be recruited, for a total of 12 participants. Participants will have Brilliance device sensors placed on two locations on their skin, which will remain for 48 hours. The sensor location will be prepared through shaving and cleaning (as applicable), placed on the skin via standard single-use adhesive pads, and baseline measurements collected. Participants may undergo activities of daily living while measurements are being collected. Light pressure and other minor perturbations may be applied to the sensors to evaluate the effect on background fluorescence. Adverse events associated with sensor placement (such as skin irritations) will be recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury
Keywords
Glomerular Filtration Rate

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Participants with Brilliance sensor placement
Arm Type
Experimental
Arm Description
Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours
Intervention Type
Device
Intervention Name(s)
Brilliance device sensor
Intervention Description
Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
Primary Outcome Measure Information:
Title
Mean Background Fluorescence
Description
Two separate Brilliance device sensors will be attached via standard adhesive pads to the left and right pectoralis major on each participant. Fluorescence measurements will be collected directly by the MediBeacon Transdermal GFR Measurement System Brilliance device, and will be continuously collected throughout the 48 hour study.
Time Frame
From the time of sensor placement to 48 hours after placement

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male and female adults age 18 and older 2 age cohorts to be recruited: 18 - 50 years of age and 51+ years or older Skin color groups to be recruited in accordance with the Fitzpatrick Skin Scale (I - VI) Participants willing to sign the Institutional Review Board (IRB) approved informed consent form prior to the initiation of any study specific procedures. Exclusion Criteria: History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape) Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial Significant scarring, tattoos or alterations in pigmentation on the standardized sensor locations that would alter sensor readings versus other areas of the skin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard B Dorshow, PhD
Organizational Affiliation
MediBeacon
Official's Role
Study Director
Facility Information:
Facility Name
St. Louis Clinical Trials
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

We'll reach out to this number within 24 hrs